Researchers in Melbourne are working on an innovative drug, CagriSema, aimed at providing a potentially life-saving treatment for individuals with type 2 diabetes. This new medication merges the active ingredient found in Ozempic with an additional appetite suppressant.
As part of a global trial, the Royal Melbourne Hospital will administer this treatment free of charge for a year to a select group of individuals who are overweight or suffer from type 2 diabetes. The study aims to address the current shortage of Ozempic, which has left many patients in Australia without adequate treatment options.
According to Associate Professor John Wentworth, an endocrinologist at the hospital, previous trials suggest that combining these two drugs enhances effectiveness compared to using Ozempic alone. Participants are anticipated to experience weight loss and improved diabetes management. However, the researchers are currently uncertain about potential safety concerns related to this new combination.
With an estimated supply shortage lasting two years, many Australians with type 2 diabetes are awaiting treatment. Glen Noonan, CEO of Diabetes Victoria, expressed enthusiasm for the trial, noting its significant potential impact on patients’ lives. The initiative aims to recruit over 2000 participants from various Australian hospitals, as well as international sites in the US, Poland, and South Africa.